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Abstract Magnesium and zinc are known to exert multiple
beneficial effects including anti-inflammatory and antioxidant
actions. To our knowledge, data on the effects of magnesium
and zinc co-supplementation on biomarkers of inflammation
and oxidative stress and gene expression related to inflamma-
tion in subjects of polycystic ovary syndrome (PCOS) are
scarce. This study was conducted to evaluate the effects of
magnesium and zinc co-supplementation on biomarkers of in-
flammation and oxidative stress and gene expression related to
inflammation in subjects with PCOS. This randomized double-
blind, placebo-controlled trial was conducted among 60 sub-
jects with PCOS diagnosed according to the Rotterdam criteria,
aged 18–40 years old. Participants were randomly assigned into
two groups to take either 250 mg of magnesium oxide plus
220 mg of zinc sulfate (containing 50 mg zinc) supplements
(n = 30) or placebo (n = 30) twice a day for 12 weeks.
Biomarkers of inflammation and oxidative stress were assessed
at baseline and at end of treatment. Gene expression related to
inflammatory cytokines was assessed in peripheral blood
mononuclear cells (PBMCs) of PCOS women with RT-PCR
method. After the 12-week intervention, compared with the
placebo, magnesium and zinc co-supplementation significantly
decreased serum high-sensitivity C-reactive protein (hs-CRP)
(− 1.6 ± 2.4 vs. + 0.1 ± 0.7 mg/L, P = 0.001) and protein car-
bonyl (PCO) (− 0.14 ± 0.28 vs. + 0.02 ± 0.07mmol/mg protein,
P = 0.002) and significantly increased plasma total antioxidant
capacity (TAC) levels (+ 60.7 ± 69.4 vs. − 1.5 ± 141.5 mmol/L,
P = 0.03). Results of RT-PCR demonstrated that compared with
the placebo, magnesium and zinc co-supplementation down-
regulated gene expression of interleukin-1 (IL-1) (P = 0.007)
and tumor necrosis factor alpha (TNF-α) (P = 0.03) in
PBMCs of subjects with PCOS. Overall, magnesium and zinc
co-supplementation, compared with the placebo, for 12 weeks
among PCOS women had beneficial effects on serum hs-CRP,
plasma PCO, TAC, and gene expression of IL-1 and TNF-α.
Clinical trial registration number: http://www.irct.ir:
IRCT201706075623N121.
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Introduction
Polycystic ovary syndrome (PCOS) is one of the most com-
mon endocrinopathies in subjects of reproductive age that
involves clinical and metabolic disorders, including oligo
menorrhoea or amenorrhoea, insulin resistance, cardiovascu-
lar abnormities, hyperandrogenemia, hirsutism, and androgen
alopecia [1]. It affects 6–15% of reproductive-aged women
among different geographic regions according to the
Rotterdam criteria [2]. Previous studies in PCOS women have
showed that hyperglycemia and insulin resistance induce an
increase in reactive oxygen species (ROS) production by pe-
ripheral blood leukocytes [3, 4] and the pro-inflammatory
transcription factor nuclear κB (NF-κB) [5] and an increase
of pro-inflammatory markers [6].
Calcium-vitamin D, magnesium-zinc-calcium-vitamin D
co-supplementation has earlier been used by other researchers.
Co-supplementation may be efficient more than single
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supplementation. In addition, previous studies have docu-
mented that calcium and vitamin D co-supplementation might
have a strong synergistic effect on metabolic profiles. For
instance, we have previously indicated that calcium and vita-
min D co-supplementation compared with calcium or vitamin
D only for 8 weeks among PCOS women had beneficial
effects on biomarkers of inflammation and oxidative stress
[7]. In addition, magnesium-zinc-calcium-vitamin D co-
supplementation resulted in significant reductions in hirsut-
ism, high-sensitivity C-reactive protein (hs-CRP), and plasma
malondialdehyde (MDA) and a significant increase in plasma
total antioxidant capacity (TAC) levels, but did not affect other
biomarkers of inflammation and oxidative stress [8]. Calcium
(1000 mg/day) and vitamin D (50,000 IU/week) co-
supplementation might significantly improve systemic in-
flammation through decreasing interleukin-6 (IL-6) and tumor
necrosis factor alpha (TNF-α) levels in vitamin D-insufficient
subjects with type 2 diabetes mellitus (T2DM) [9]. However,
magnesium supplementation as magnesium oxide at dosage
of 250 mg/day for 8 weeks in overweight women did not
influence inflammatory markers [10]. In addition, no signifi-
cant effect in hs-CRP concentrations was seen after the intake
of 10 mg rosuvastatin for 4 months with or without zinc sup-
plements (30 mg/day) in subjects with atherosclerosis [11].
According to our knowledge, data on the effects of magne-
sium and zinc co-supplementation on biomarkers of inflam-
mation and oxidative stress and gene expression related to
inflammation in subjects with PCOS are scarce. Therefore,
we hypothesized that takingmagnesium plus zincmight affect
metabolic status of PCOS population. We investigated this
aim by conducting the effects of magnesium and zinc co-
supplementation on biomarkers of inflammation and oxida-
tive stress, and gene expression related to inflammation in
women with PCOS.
Patients and Methods
The current randomized double-blind, placebo-controlled tri-
al, registered in the Iranian website for registration of clinical
trials as http://www.irct.ir: IRCT201706075623N121, was
performed among 60 subjects with PCOS diagnosed
according to the Rotterdam criteria [12], aged 18–40 years
old who were referred to the Naghavi Clinic in Kashan, Iran,
from June 2017 to August 2017. The present study was
carried out in accordance with the Declaration of Helsinki
and Good Clinical Practice guidelines, and written informed
consent was taken from all participants. We excluded women
who were pregnant during the intervention, and metabolic
disorders, including androgen-secreting tumors, thyroid dys-
function, diabetes or impaired glucose tolerance at enrollment,
insulin injection, and taking anti-inflammatory drugs.
Study Design
At first, participants were matched according to BMI (< 25 and
≥ 25 kg/m2), age (< 30 and ≥ 30 years), and phenotypes A (14
subjects in each group) and D (16 subjects in each group) of
PCOS. Then, PCOS women were randomized into two groups
to take either 250 mg of magnesium oxide plus 220 mg of zinc
sulfate (containing 50 mg zinc) supplements (n = 30) or place-
bo (n = 30) twice a day for 12 weeks. Shape and size of mag-
nesium and zinc supplements and placebos were similar and
manufactured by 21st Century Pharmaceutical Company (AZ,
USA), Alhavi Pharmaceutical Company (Tehran, Iran), and
Barij Essence Pharmaceuticals (Kashan, Iran), respectively.
Randomization assignment was performed using computer-
generated random numbers. Randomization and allocation
concealment were done from the researchers and participants
and were carried out by a trained staff member at the gynecol-
ogy clinic. Participants were asked not to alter their routine
physical activity or usual dietary intakes during the study and
were asked not to consume any supplements that might influ-
ence related markers during the intervention. All participants
provided 3-day dietary records and three physical activity re-
cords to verify that they maintained their usual diet and phys-
ical activity during the intervention. Both dietary records and
physical activity were taken at the baseline and weeks 3, 6, 9,
and 12 during the intervention. To obtain information on par-
ticipant nutrient intake based on these 3-day food diaries, we
used Nutritionist IV software (First Databank, San Bruno, CA)
modified for Iranian foods.
Assessment of Anthropometric Measures
A trained midwife at the clinic took anthropometric measure-
ments at baseline and 12 weeks following the intervention.
Height and weight (Seca, Hamburg, Germany) were measured
while the participants wore light clothing and no shoes. Body
mass index (BMI) was calculated as weight (in kilograms)
divided by height (in meters) squared.
Assessment of Outcomes
Inflammatory markers were considered as the primary out-
comes, and biomarkers of oxidative stress were considered
as the secondary outcomes.
Biochemical Assessment
Twenty-milliliter fasting blood samples were collected at the
baseline and after the 12-week intervention at Kashan
Reference Laboratory, Kashan, Iran. Serum hs-CRP values
were quantified using an ELISA kit (LDN, Nordhorn,
Germany) with inter- and intra-assay coefficient variances
(CVs) of 4.8 to 6.5%, respectively. The plasma nitric oxide
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(NO) using Griess method [13] was determined. Plasma TAC
concentrations using the method of ferric-reducing antioxi-
dant power developed by Benzie and Strain [14], total gluta-
thione (GSH) using the method of Beutler et al. [15], and
MDA concentrations by the thiobarbituric acid reactive sub-
stance spectrophotometric test [16] were determined. CVs for
plasma TAC, GSH, and MDA were lower than 5%, respec-
tively. Plasma protein carbonyl (PCO) levels were quantified
using a spectrophotometric method [17] with inter- and intra-
assay CVs of lower than 5%.
Isolation of Lymphocyte, RNA Extraction, and cDNA
Synthesis
Lymphocytes were isolated using 50% Percoll solution
(Sigma-Aldrich, Dorset, UK) gradient by centrifugation for
20 min and 3000 rpm at 4 °C [18]. Total RNAwas extracted
based on acid guanidinium-phenol-chloroform procedure
using RNX™-plus reagent (Cinnacolon, Tehran, Iran) accord-
ing to the manufacturer’s instructions. RNAs were treated
with DNase I (Fermentas, Lithuania) for the elimination of
any genomic DNA contamination. Concentration, integration,
and purity of RNA samples were determined by spectrometry
and gel electrophoresis. Three micrograms of total RNAwas
used for cDNA synthesis with random hexamer and oligo (dT)
18 primers through RevertAid™ Reverse Transcriptase
(Fermantase, Canada) in total 20 μL reaction mixture [18].
Real-Time PCR Analysis
Appropriate primers for interleukin-1 (IL-1), IL-8, TNF-α,
transforming growth factor beta (TGF-β), vascular endotheli-
al growth factor (VEGF), and glyceraldehyde-3-phosphate
dehydrogenase—as an internal control—were designed
(Table 1). Quantitative real-time PCR was performed by the
LightCycler® 96 sequence detection systems (Roche
Diagnostics, Rotkreuz, Switzerland) using 4 μL of 5×
EvaGreen I master mix (Salise Biodyne, Japan), 10 ng
cDNA, and 200 nM of each forward and reverse primers in
final volume of 20 μL. The PCR was performed through the
following instruction: an initial denaturation at 95 °C for
10 min, followed by 40 cycles of denaturation at 95 °C for
10 s, annealing at 54–62.1 °C for 15 s, and extension at 72 °C
for 30 s. The specificity of PCR products was evaluated by
1.5% agarose gel electrophoresis and melting curve analysis.
All experiments were performed at least in triplicate.
Statistical Methods
To calculate the sample size, we used the standard formula
suggested for clinical trials by considering type 1 error (α)
of 0.05 and type 2 error (β) of 0.20 (power = 80%). Based
on a previous study [19], we used 1391.56 ng/mL as SD and
1120.0 ng/mL as the difference in mean (d) of hs-CRP as
primary variable. Based on this, we needed 25 subjects in each
group. Considering a dropout of 5 subjects per group, we
calculated to have 30 subjects per group.
The Shapiro-Wilk test was applied to control the normal
distribution of variables. The analyses were carried out based
on intention-to-treat (ITT) principle. To detect differences in
anthropometric measures, macro- and micro-nutrient intakes,
and gene expression related to inflammation between the two
groups, we used independent t test. To determine the effects of
magnesium and zinc co-supplementation on biomarkers of
inflammation and oxidative stress, we used one-way repeated
measures analysis of variance. Adjustment for changes in
baseline values of biochemical parameters was performed by
analysis of covariance (ANCOVA) using general linear
models. The P value of < 0.05 was considered statistically
significant. All statistical analyses used the Statistical
Package for Social Science version 18 (SPSS Inc., Chicago,
IL, USA).
Results
Firstly, we invited 75 subjects with PCOS; however, 15 sub-
jects were excluded from the study because of not meeting
inclusion criteria [(not meeting inclusion criteria (n = 10) and
not living in Kashan (n = 5)] (Fig. 1). As demonstrated in the
study flow diagram, during the intervention phase of the study,
three participants in the placebo group and four participants in
the intervention group due to personal reasons were excluded.
Finally, 60 participants [placebo (n = 27) and intervention
(n = 26)] completed the trial. However, as the analysis was
based on ITT principle, all 60 participants (30 in each group)
were included in the final analysis.
Participants’ mean age, height, and weight and BMI at the
baseline and end of trial were not statistically different be-
tween the two groups (data not shown).
Based on the 3-day dietary records obtained at the baseline,
end of treatment, and throughout the study, we found no sig-
nificant effect in mean dietary macro- and micro-nutrient in-
takes between the two groups (data not shown).
After the 12-week intervention, compared with the place-
bo, magnesium and zinc co-supplementation significantly in-
creased serum magnesium (+ 0.21 ± 0.24 vs. − 0.05 ±
0.17 mg/dL, P < 0.001) and zinc (+ 6.6 ± 3.9 vs. − 0.6 ±
3.9 mg/dL, P < 0.001). In addition, compared with the place-
bo, magnesium and zinc co-supplementation significantly de-
creased serum hs-CRP (− 1.6 ± 2.4 vs. + 0.1 ± 0.7 mg/L, P =
0.001) and PCO (− 0.14 ± 0.28 vs. + 0.02 ± 0.07 mmol/mg
protein, P = 0.002) and significantly increased plasma TAC
levels (+ 60.7 ± 69.4 vs. − 1.5 ± 141.5 mmol/L, P = 0.03)
(Table 2). We did not observe any significant effect of
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magnesium and zinc co-supplementation on plasma NO,
GSH, and MDA compared with the placebo.
Baseline values of plasma NO (P = 0.01), TAC (P = 0.01),
and GSH (P = 0.01) were significantly different between the
two groups. Therefore, we controlled the analyses for baseline
values. When we adjusted the analysis for baseline values of
biochemical parameters, plasma TAC (P = 0.14) became non-
significant, while plasma NO (P = 0.03) became statistically
significant, and other findings did not alter (Table 3).
Results of RT-PCR demonstrated that compared with the
placebo, magnesium and zinc co-supplementation downregu-
lated gene expression of IL-1 (P = 0.007) and TNF-α (P =
0.03) in PBMCs of subjects with PCOS (Fig. 2).
We did not observe any significant effect of magnesium
and zinc co-supplementation on gene expression of IL-8,
TGF-β, and VEGF compared with the placebo (Fig. 3).
Discussion
To our knowledge, data on magnesium and zinc co-
supplementation on biomarkers of inflammation and oxida-
tive stress and gene expression related to inflammation among
PCOS women are limited.We found that magnesium and zinc
co-supplementation, compared with the placebo, for 12 weeks
among PCOSwomen had beneficial effects on serum hs-CRP,
plasma PCO, TAC, and gene expression of IL-1 and TNF-α,
but did not affect NO, GSH,MDA, and gene expression of IL-
8, TGF-β, and VEGF. It must be considered that there was a
significant difference in baseline levels of plasma NO, TAC,
and GSH between the magnesium-zinc and the placebo
groups at study baseline. This difference might have been
occurred due to several reasons. The diagnosis of PCOS in
our study was done based on the Rotterdam criteria.
Randomized (n=60) 
Allocated to placebo (n=30) 
Lost to follow-up due to 
personal reasons (n=3) 
Analyzed (n=30) 
Allocated to intervention (n=30) 
Lost to follow-up due to personal 
reasons (n=4) 
Analyzed (n=30) 
Assessed for eligibility (n=75) 
Excluded (n=15)  
- Not meeting inclusion criteria (n=10)  
- Not living in Kashan (n=5)  
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Fig. 1 Summary of patient flow
diagram
Table 1 Specific primers used
for real-time quantitative PCR Gene Primer Product size (bp) Annealing temperature (°C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
IL-1 F: GCTTCTCTCTGGTCCTTGG 174 56
R: AGGGCAGGGTAGAGAAGAG
IL-8 F: GCAGAGGGTTGTGGAGAAGT 150 56
R: ACCCTACAACAGACCCACAC
TNF-α F: GTCAACCTCCTCTCTGCCAT 188 52
R: CCAAAGTAGACCTGCCCAGA
TGF-β F: TTGAGACTTTTCCGTTGCCG 227 56
R: CGAGGTCTGGGGAAAAGTCT
VEGF F: CTTCTGAGTTGCCCAGGAGA 216 54
R: CTCACACACACACAACCAGG
GAPDH glyceraldehyde-3-phosphate dehydrogenase, IL-1 interleukin-1, IL-8 interleukin-8, TNF-α tumor necro-
sis factor alpha, TGF-β transforming growth factor beta, VEGF vascular endothelial growth factor
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Therefore, different patients might had different plasma NO,
TAC, and GSH levels, which could in turn lead to a different
mean of NO, TAC, and GSH at study baseline. Furthermore,
we did not randomize participants based on their NO, TAC,
and GSH levels because all participants had PCOS. Random
assignment to two groups was done after stratification for
BMI (< 25 and ≥ 25 kg/m2), age (< 30 and ≥ 30 years), and
phenotypes A and D of PCOS, and random assignment was
done by the use of computer-generated random numbers.
Therefore, the difference in NO, TAC, and GSH levels be-
tween the two groups was occurred by random. In addition,
when we adjusted the analyses for baseline values, no signif-
icant changes in our findings were observed except for TAC
and No levels.
Subjects with PCOS are susceptible to some metabolic ab-
errations, including hormonal disturbances and increased bio-
markers of inflammation and oxidative stress [7, 20]. The
current study demonstrated that magnesium and zinc co-
supplementation for 12 weeks to PCOS subjects led to signif-
icant reductions in serum hs-CRP levels and gene expression
of IL-1 and TNF-α, but could not influence plasma NO levels
and gene expression of IL-8, TGF-β, and VEGF. Supporting
our study, results of a meta-analysis study indicated that mag-
nesium supplementation decreased CRP concentrations
among individuals with inflammation [21]. Some cross-
sectional studies have documented inverse relationships be-
tween magnesium intake and some inflammatory markers,
such as hs-CRP and IL-6 [22, 23]. In addition, a significant
reduction in serum CRP levels was observed following the
supplementation of magnesium as oral magnesium citrate at
a dosage of 300 mg/day for 5 weeks among patients with heart
failure [24]. Maternal magnesium supplementation as magne-
sium chloride suppressed cytokine/chemokine levels in the
amniotic fluid and placentas in a rat model [25]. Moreover,
neonates with sepsis who received zinc supplements in addi-
tion to antibiotics demonstrated a significant reduction in
Table 2 Metabolic profiles at baseline and after the 12-week intervention in subjects with polycystic ovary syndrome
Placebo group (n = 30) Magnesium-zinc group (n = 30) Pa
Baseline End of trial Change Baseline End of trial Change
Magnesium (mg/dL) 1.81 ± 0.32 1.76 ± 0.31 − 0.05 ± 0.17 1.84 ± 0.29 2.05 ± 0.31 0.21 ± 0.24 < 0.001
Zinc (mg/dL) 84.9 ± 11.6 84.3 ± 11.1 − 0.6 ± 3.9 80.4 ± 12.4 86.3 ± 13.4 6.6 ± 5.0 < 0.001
hs-CRP (mg/L) 5.1 ± 1.9 5.2 ± 1.9 0.1 ± 0.7 4.4 ± 2.6 2.8 ± 1.4 − 1.6 ± 2.4 0.001
NO (μmol/L) 42.5 ± 7.2 43.1 ± 7.0 0.6 ± 6.3 38.6 ± 4.2 37.9 ± 4.7 − 0.6 ± 5.1 0.39
TAC (mmol/L) 795.0 ± 132.5 793.5 ± 172.8 − 1.5 ± 141.5 724.7 ± 64.0 785.4 ± 73.1 60.7 ± 69.4 0.03
GSH (μmol/L) 512.5 ± 87.2 541.5 ± 80.3 29.0 ± 68.0 571.1 ± 99.2 607.4 ± 143.1 36.2 ± 102.3 0.74
MDA (μmol/L) 2.5 ± 0.6 2.7 ± 1.1 0.2 ± 1.1 2.7 ± 0.3 2.5 ± 0.2 − 0.2 ± 0.2 0.11
PCO (nmol/mg protein) 2.67 ± 0.34 2.70 ± 35 0.02 ± 0.07 2.59 ± 0.39 2.45 ± 0.41 − 0.14 ± 0.28 0.002
All values are means ± SDs
GSH total glutathione, hs-CRP high-sensitivity C-reactive protein,MDAmalondialdehyde,NO nitric oxide,PCO protein carbonyl, TAC total antioxidant
capacity
aP values represent the time × group interaction (computed by analysis of the one-way repeated measures ANOVA)
Table 3 Adjusted changes in
metabolic profile of patients with
polycystic ovary syndrome
Placebo group (n = 30) Magnesium-zinc group (n = 30) Pa
Magnesium (mg/dL) − 0.05 ± 0.03 0.2 ± 0.03 < 0.001
Zinc (mg/dL) − 0.5 ± 0.8 6.5 ± 0.8 < 0.001
hs-CRP (mg/L) 0.3 ± 0.2 − 1.8 ± 0.2 < 0.001
NO (μmol/L) 1.5 ± 1.0 − 1.5 ± 1.0 0.03
TAC (mmol/L) 7.6 ± 20.5 51.5 ± 20.5 0.14
GSH (μmol/L) 24.3 ± 16.1 40.9 ± 16.1 0.47
MDA (μmol/L) 0.1 ± 0.1 − 0.1 ± 0.1 0.18
PCO (nmol/mg protein) 0.03 ± 0.03 − 0.15 ± 0.03 0.001
All values are means ± SEs. Values are adjusted for baseline values
GSH total glutathione, hs-CRP high-sensitivity C-reactive protein,MDAmalondialdehyde, NO nitric oxide, PCO
protein carbonyl, TAC total antioxidant capacity
a Obtained from ANCOVA
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inflammatory cytokines, including IL-6 and TNF-α [26].
Supplementation with 30 mg/day of zinc supplements as zinc
gluconate for 8 weeks to obese women resulted in a significant
reduction in hs-CRP concentrations [27]. However, supple-
mentation with 250 mg of magnesium as magnesium oxide
for 8 weeks did not affect inflammatory markers in middle-
aged overweight women [10]. In addition, no significant dif-
ference in hs-CRP values was seen following the intake of
10 mg rosuvastatin for 4 months with or without zinc supple-
ments (30 mg/day) in subjects with atherosclerosis [11].
Biochemical levels and gene expression of some inflammato-
ry cytokines and mediators have been shown to be elevated in
PCOS women [28]. Prior studies have documented that in-
creased inflammatory factors play a main role in
hyperinsulinemia and the vascular inflammation process
through multiple actions [29, 30]. Magnesium intake may
decrease inflammatory factors due to its antagonism to calci-
um, the ion playing an important role in inflammation [31]. In
addition, zinc intake may be associated with the regulation of
NF-κB activation via anti-inflammatory protein A20 and per-
oxisome proliferator-activated receptor-α signaling pathway
[27]. NF-κB as a component of the adhesion molecule
upregulation process increases CRP concentrations and in-
flammatory markers, including IL-1β and TNF-α [32].
Our study demonstrated that magnesium and zinc co-
supplementation for 12 weeks to women with PCOS resulted
in a significant rise in plasma TAC and a significant reduction
in plasma PCO levels, but did not influence plasma GSH
levels. In line with our study, potassium magnesium citrate
supplementation for 4 weeks significantly decreased bio-
markers of oxidative stress in prehypertensive and hyperten-
sive subjects [33]. Furthermore, high magnesium diet has
been shown to attenuate aldosterone-induced rise in
NADPH oxidase activity in the kidneys of mice with geneti-
cally low intracellular magnesium levels [34]. Zinc supple-
mentation could also attenuate diabetes-induced oxidative
stress in circulation as well as in cardiac and hepatic tissues
in diabetic rats [35]. Unlike our study, the kidney and serum
levels of MDA were increased significantly in non-diabetic
rats treated with magnesium sulfate for 10 days [36].
Furthermore, Tang et al. [37] demonstrated that zinc supple-
mentation did not influence MDA concentrations in rats with
severe acute pancreatitis. Increased oxidative stress has been
implicated in the pathogenesis of insulin resistance,
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Fig. 3 Effect of 12-week supplementation with magnesium plus zinc or
placebo on expression ratio of IL-8, TGF-β, and VEGF gene in blood
mononuclear cells of PCOS women. IL-1 interleukin-1, IL-8 interleukin-
8, PCOS polycystic ovary syndrome, TNF-α tumor necrosis factor alpha,
TGF-β transforming growth factor beta, VEGF vascular endothelial
growth factor
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Fig. 2 Effect of 12-week
supplementation with magnesium
plus zinc or placebo on
expression ratio of IL-1 and TNF-
α gene in blood mononuclear
cells of PCOS women
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dyslipidemia, and diabetes mellitus [38]. In addition, in-
creased biomarkers of oxidative stress associated with in-
creased risk of atherosclerosis [39]. Magnesium intake might
decrease oxidative stress via reducing ROS production [40]
and increasing glutathione-peroxidase activity [41].
Furthermore, zinc may contribute to the antioxidant role
through its ability to compete with transition metals iron and
copper for the binding sites on the cell membrane [35]. Iron
and copper ions catalyze the production of lipid peroxides,
and thereby, replacement of these metals by zinc in the plasma
membrane could inhibit lipid peroxides in insulin resistance
condition.
The current study had a number of limitations. Due to lim-
ited funding, we could not assess the effects of magnesium
and zinc co-supplementation on gene expression related to
insulin resistance and lipid in the current study. In addition,
further studies are needed with single supplementation of each
compared with co-supplementation to evaluate the beneficial
effects on biomarkers of inflammation and oxidative stress.
Overall, our study demonstrated that magnesium and zinc
co-supplementation, compared with the placebo, for 12 weeks
among PCOSwomen had beneficial effects on serum hs-CRP,
plasma PCO, TAC, and gene expression of IL-1 and TNF-α,
but did not affect NO, GSH,MDA, and gene expression of IL-
8, TGF-β, and VEGF. This suggests that magnesium and zinc
co-supplementation may confer advantageous therapeutic po-
tential for subjects with PCOS management. Further research
is needed in other patients with longer periods to determine the
safety of this supplemental approach.
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